AE	Adverse event
AIs	Aromatase Inhibitors
AR	Androgen receptor
BC	Breast Cancer
CDK 4/6	Cyclin-Dependent Kinase 4/6
CDKi	CDK inhibitor
CIs	Confidence Intervals
CIP	CDK-interacting protein
EMA	European Medicine Agency
ER	Estrogen Receptor
ET	Endocrine Therapy
FDA	Food and Drug Administration
HER2	Human Epidermal Growth Factor Receptor 2
HR	Hormone Receptor
INK4	inhibitor of CDK4
KIP	CDK-kinase inhibitory protein
LAR	Luminal androgen receptor
MEK	Mitogen-activated protein kinase kinase
mTOR	Mammalian Target Of Rapamycin
PD-L1	Programmed Cell Death Ligand-1
PI3K	Phosphatidylinositol 3-kinase
PIK3	Phosphoinositide 3-kinase
pRB	Retinoblastoma-associated proteins
NSAI	Non-Steroidal Aromatase Inhibitors
ORR	Objective Response Rate
OS	Overall Survival
PFS	Progression Free Survival
RBC	Residual Cancer Burden
TNBC	Triple negative breast cancer
Treg	Regulatory T cells